Organon & Co. (NYSE:OGN) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On July 2, Organon & Co. (NYSE:OGN) announced that its Phase 2 ELENA proof-of-concept study did not meet ...

With a new leadership team and fast-track designation from the FDA, Prescient Therapeutics is laser focused on development of ...

Serving the community, advancing knowledge The Institute for Community Mental Health (ICMH) at the University of Delaware stands as a pioneering initiative led by the clinical science faculty within ...

ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

Mosaic Therapeutics In-Licenses Two Clinical-Stage Oncology Programs From Astex Pharmaceuticals for Development as Proprietary Combination Therapies Provided by Business Wire Apr 24, 2025 7:24am ...

Oncolytics Biotech® Names New CEO To Accelerate Momentum In Immunotherapy Programs. Date. 2025-06-11 07:01:11. ... With a renewed focus and sharpened clinical development plan, ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the ...

The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the ...

Northeastern State University’s School of Social Work has been awarded a transformative $2.3 million grant from the Health ...